Dicerna Pharma (DRNA) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel
May 15, 2018 7:00 AM EDTStifel raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $18.00 (from $17.00) while maintaining a Buy rating.
Analsyt Stephen Willey commented, "We believe the recently-announced settlement of the Alnylam litigation now provides improved visibility into both longer-term balance sheet runway and ongoing/future business development... More
